These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2579238)

  • 1. The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors.
    Chrzanowski FA; McGrogan BA; Maryanoff BE
    J Med Chem; 1985 Mar; 28(3):399-400. PubMed ID: 2579238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol.
    Philipp AH; Humber LG; Voith K
    J Med Chem; 1979 Jul; 22(7):768-73. PubMed ID: 571917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic activity of four analogs of butaclamol.
    Collu R; Bouvier C; Basak A; Dugas H
    Pharmacol Res Commun; 1985 Dec; 17(12):1153-7. PubMed ID: 2419927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol.
    Humber LG; Bruderlein FT; Philipp AH; Götz M
    J Med Chem; 1979 Jul; 22(7):761-7. PubMed ID: 571916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3H]dihydroergocryptine binding to bovine striatal membranes defined by a low d-butaclamol concentration: antagonism by substituted benzamides.
    Lin CW; Maayani S; Wilk S
    Biochem Pharmacol; 1981 Jun; 30(11):1305-14. PubMed ID: 6168265
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of the butaclamol template in a search for antipsychotic agents with lessened side effects.
    Kukla MJ; Bloss JL; Brougham LR
    J Med Chem; 1979 Apr; 22(4):401-6. PubMed ID: 34721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic receptors: stereoselectivity for neuroleptic enantiomers.
    Seeman P; Westman K; Protiva M; Jílek J; Jain PC; Saxena AK; Anand N; Humber L; Philipp A
    Eur J Pharmacol; 1979 Jun; 56(3):247-51. PubMed ID: 38971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple receptors for brain dopamine.
    Titeler M; Weinreich P; Sinclair D; Seeman P
    Proc Natl Acad Sci U S A; 1978 Mar; 75(3):1153-6. PubMed ID: 418405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The conformation of dopamine at its receptor: binding of monohydroxy-2-aminotetralin enantiomers and positional isomers.
    Tedesco JL; Seeman P; McDermed JD
    Mol Pharmacol; 1979 Sep; 16(2):369-81. PubMed ID: 514252
    [No Abstract]   [Full Text] [Related]  

  • 10. Histamine-, norepinephrine-, and dopamine-sensitive central adenylate cyclases: effects of chlorpromazine derivatives and butaclamol.
    Palmer GC; Wagner HR; Palmer SJ; Manian AA
    Arch Int Pharmacodyn Ther; 1978 Jun; 233(2):314-25. PubMed ID: 687395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the stereoisomers of butaclamol on neurotensin content in discrete regions of the rat brain.
    Bissette G; Dauer WT; Kilts CD; O'Connor L; Nemeroff CB
    Neuropsychopharmacology; 1988 Dec; 1(4):329-35. PubMed ID: 2472151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsatile growth hormone and prolactin: effects of (+) butaclamol, a dopamine receptor blocking agent.
    Willoughby JO; Brazeau P; Martin JB
    Endocrinology; 1977 Oct; 101(4):1298-303. PubMed ID: 908278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of R(+)-ADTN in dopamine receptor binding assays.
    Davis A; Poat JA; Woodruff GN
    Eur J Pharmacol; 1980 May; 63(2-3):237-8. PubMed ID: 6155278
    [No Abstract]   [Full Text] [Related]  

  • 14. Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors.
    Schrell UM; Fahlbusch R; Adams EF; Nomikos P; Reif M
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1669-71. PubMed ID: 1699967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states.
    George SR; Watanabe M; Seeman P
    J Neurochem; 1985 Apr; 44(4):1168-77. PubMed ID: 2579204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic drugs inhibit prolactin release from rat anterior pituitary cells in culture by a mechanism not involving the dopamine receptor.
    West B; Dannies PS
    Endocrinology; 1979 Apr; 104(4):877-80. PubMed ID: 436760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermodynamic analysis of antagonist and agonist interactions with dopamine receptors.
    Duarte EP; Oliveira CR; Carvalho AP
    Eur J Pharmacol; 1988 Mar; 147(2):227-39. PubMed ID: 2452751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and X-ray data of novel potential antipsychotic agents. Substituted 7-phenylquinolizidines: stereospecific, neuroleptic, and antinociceptive properties.
    Imhof R; Kyburz E; Daly JJ
    J Med Chem; 1984 Feb; 27(2):165-75. PubMed ID: 6198519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional in vivo binding of [3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors.
    Köhler C; Fuxe K; Ross SB
    Eur J Pharmacol; 1981 Jul; 72(4):397-402. PubMed ID: 7274333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further evidence for inhibition of episodic luteinizing hormone release in ovariectomized rats by stimulation of dopamine receptors.
    Drouva SV; Gallo RV
    Endocrinology; 1977 Mar; 100(3):792-8. PubMed ID: 95702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.